Handelsavisen
prelaunch
Companies Healthcare OSRH.O
OS
OSRH.O NASDAQ Biotechnology & Life-Science Tools

OSR Holdings Inc

$0,42
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
13,9M USD
P/E
EV / Rev
Div yield
Op margin
-631,0 %
ROE
-23,2 %
Net margin
-619,8 %
Debt / equity
0,06
Beta
52w range
Volume
11,8k
Day range
$0,45–$0,50
Prev close
$0,48
Open
$0,48
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

OSR Holdings Inc is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic products and services.

Business. OSR Holdings Inc (OSRH.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target10,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
10,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
-23,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning OSRH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to OSRH.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Osr Holdings Inc (OSRH.O) has recorded two notable additions to its shareholder base, marking the first analysis for this ticker. As of the most recent data, the company has no analyst coverage, no index memberships, and no reported officers, with a total of three top holders identified. The first significant change involves investor ID 465, who added a position of 54,402 shares as of December 31, 2025. This holding represents a value of $0.030682 million and constitutes a weight of approximately 4.45e-07 percent of the total shares. A second notable addition was made by investor ID 499, who acquired 4,476 shares as of March 31, 2026. This position is valued at $0.002699 million, representing a weight of approximately 4.79e-07 percent. These changes are significant as they represent the initial baseline for tracking institutional or significant holder activity for OSRH.O. With no prior basis for delta computation, these entries establish the starting point for monitoring future shifts in ownership structure for the company.

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    OSR Holdings Inc (OSRH.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupBiotechnology & Life-Science Tools
    AI synthesis
    GENERATED

    OSR Holdings Inc exhibits a highly leveraged capital structure with a debt-to-equity ratio of 0.06, indicating minimal reliance on debt financing. However, the company's liquidity position is weak, as evidenced by a current ratio of 0.16, suggesting significant short-term liquidity constraints. The price-to-book ratio of 0.27 and price-to-tangible-book ratio of 0.27 further indicate that the company's market value is significantly below its book value, reflecting poor investor sentiment or asset impairment.

    Profitability metrics are severely negative, with a return on equity of -0.232 and a return on assets of -0.1052, both well below industry norms. The company reported a net loss of $18.01 million and an operating loss of $18.34 million, indicating a lack of operational efficiency and revenue generation. Gross profit of $592,910 is minimal relative to total revenue of $2.91 million, suggesting high cost structures or low pricing power.

    Geographically and segment-wise, OSR Holdings Inc's revenue concentration is not disclosed in the available data. However, the company's exposure to the healthcare diagnostics industry implies a high degree of specialization, with potential risks tied to regulatory changes and technological obsolescence. The absence of detailed segment reporting limits the ability to assess diversification or growth drivers within the business.

    The company's growth trajectory is negative, with no clear signs of improvement in the near term. Analysts have assigned a mean price target of $10.00, which is significantly higher than the current market price of $0.64, but the lack of strong buy recommendations (0) and the presence of only one buy recommendation suggest limited confidence in the company's ability to deliver returns. The operating cash flow of -$4.33 million and free cash flow of -$17.93 million indicate a cash burn rate that could threaten the company's solvency if not addressed.

    Risk factors include a medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is currently low, but the company's capital structure and financial performance suggest a potential need for equity financing in the future, which could dilute existing shareholders. The absence of capital expenditures and the negative operating cash flow further underscore the company's financial instability.

    Recent events, including the lack of positive analyst sentiment and the absence of disclosed capital expenditures, suggest a challenging operating environment. The company's financial performance and risk profile indicate a need for significant operational and strategic improvements to restore investor confidence and achieve profitability.

    Osr Holdings Inc (OSRH.O) has recorded two notable additions to its shareholder base, marking the first analysis for this ticker. As of the most recent data, the company has no analyst coverage, no index memberships, and no reported officers, with a total of three top holders identified. The first significant change involves investor ID 465, who added a position of 54,402 shares as of December 31, 2025. This holding represents a value of $0.030682 million and constitutes a weight of approximately 4.45e-07 percent of the total shares. A second notable addition was made by investor ID 499, who acquired 4,476 shares as of March 31, 2026. This position is valued at $0.002699 million, representing a weight of approximately 4.79e-07 percent. These changes are significant as they represent the initial baseline for tracking institutional or significant holder activity for OSRH.O. With no prior basis for delta computation, these entries establish the starting point for monitoring future shifts in ownership structure for the company.

    Key takeaways
    • OSR Holdings Inc is operating at a significant loss, with a net loss of $18.01 million and an operating loss of $18.34 million.
    • The company's liquidity position is weak, with a current ratio of 0.16 and a negative net cash position.
    • Profitability metrics are severely negative, with a return on equity of -0.232 and a return on assets of -0.1052.
    • Analysts have assigned a mean price target of $10.00, but the lack of strong buy recommendations suggests limited confidence in the company's future performance.
    • The company's capital structure and financial performance indicate a potential need for equity financing, which could dilute existing shareholders.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,42
    Market cap
    $21.2M
    Enterprise value
    $25.5M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    0.3x
    P / Tangible book
    0.3x
    Tangible book
    $77.6M
    Net cash
    -$4.3M
    Current ratio
    0.2
    Debt / equity
    0.1
    ROA
    -10.5%
    ROE
    -23.2%
    Cash conversion
    24.0%
    CapEx / revenue
    -6.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryBiotechnology & Life-Science Tools27,7B node revenueIQV 58,8%CRL 14,5%MEDP 9,1%ALKS 5,3%PIII 5,3%ORGO 2,0%NAGE 0,5%SPRY 0,3%Other 4,2%
    Source: company disclosures · own-taxonomy revenue-covered setOSRH 0,0% · rank #49 of 78

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs OSRH · multiples and returns
    IQ
    IQV
    Iqvia Holdings Inc
    $181,94
    30,9B USD
    P/E
    22,7x
    vs self
    Div yield
    vs self
    ROE
    21,9 %
    +45,1 vs self
    CR
    CRL
    Charles River Laboratories
    $230,87
    11,4B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -4,6 %
    +18,6 vs self
    ME
    MEDP
    Medpace Holdings Inc
    $576,00
    16,7B USD
    P/E
    34,4x
    vs self
    Div yield
    vs self
    ROE
    75,4 %
    +98,6 vs self
    AL
    ALKS
    Alkermes PLC
    $49,53
    8,2B USD
    P/E
    39,8x
    vs self
    Div yield
    vs self
    ROE
    8,4 %
    +31,6 vs self
    PI
    PIII
    P3 Health Partners Inc
    $10,20
    73,8M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    95,3 %
    +118,5 vs self
    OR
    ORGO
    Organogenesis Holdings Inc
    $2,38
    306,2M USD
    P/E
    9,0x
    vs self
    Div yield
    vs self
    ROE
    8,5 %
    +31,7 vs self
    NA
    NAGE
    Niagen Bioscience Inc
    $3,53
    281,1M USD
    P/E
    17,4x
    vs self
    Div yield
    vs self
    ROE
    22,7 %
    +45,9 vs self
    SP
    SPRY
    Ars Pharmaceuticals Inc
    $5,51
    547,1M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -149,9 %
    -126,7 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-07-20

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$10,00 · Median $10,00
    Low $10,00High $10,00

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$10,00
    Mean$10,00
    Median$10,00
    High$10,00
    Spot$0,42
    +2277.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-631,0 %Below median
    Net Margin-619,8 %Below median
    ROE-23,2 %Above median
    Capex / Rev-6,1 %Below median
    D/E0,06Bottom quartile
    Cash Conv0,24Bottom quartile

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • OSR Holdings Inc Market data — financials · 2026-05-28
    • OSR Holdings Inc Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M

    Insider activity

    — missing data

    Short positioning

    1.7Mshares short+19.5% vs prior
    2.03days to cover
    37.5%short of daily vol
    11.7Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    OSRH.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorM&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 38.0%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -134.0%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -17.7%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 97.6%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): -26.9%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -14.9%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 83.3%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 80.8%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -2.3%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -56.8%Derived (calculated)
    • Gross margin (FY 2025-12-31): 20.4%Derived (calculated)
    • Current ratio (FY 2025-12-31): 0.16xDerived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 397.8%Derived (calculated)
    • Revenue (annual): USD 2.91MSEC XBRL filing
    • Gross profit (annual): USD 592.9KSEC XBRL filing
    • Total assets (annual): USD 171.24MSEC XBRL filing
    • Operating cash flow (annual): USD -4.33MSEC XBRL filing
    • Shares outstanding (annual): 26.6MSEC XBRL filing
    • Current assets (annual): USD 2.82MSEC XBRL filing
    • Current liabilities (annual): USD 17.17MSEC XBRL filing
    • R&D expense (annual): USD 318.45KSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
    • Operating income (annual): USD -18.34MSEC XBRL filing
    • Pre-tax income (annual): USD -28.89MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-29 22:34 UTCEVENTHa Price Listing OSRH remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 30 consecutive trading days (last close $0.3206). cure deadline 2027-01-17 (172 days remaining).
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDER2 institutional position changes flagged
    2026-06-17FILINGCURRENT REPORT →
    2026-06-11FILINGCURRENT REPORT →
    2026-06-02FILINGCURRENT REPORT →
    2026-05-26FILINGPROXY STATEMENT →
    2026-05-13FILINGQUARTERLY REPORT →
    2026-04-30FILINGCURRENT REPORT →
    2026-04-22FILINGCURRENT REPORT →
    2026-04-09FILINGCURRENT REPORT →
    2026-04-02FILINGCURRENT REPORT →
    2026-03-31FILINGANNUAL REPORT →
    2026-03-16FILINGCURRENT REPORT →
    2026-03-10FILINGCURRENT REPORT →
    2025-02-14 00:00 UTCINSIDER4 insider transactions — 2025-02
    2025-02-14 00:00 UTCINSIDER4 insider transactions — 2025-02
    2023-03-23 00:00 UTCINSIDER6 insider transactions — 2023-03 3 derivative
    2023-03-23 00:00 UTCINSIDER6 insider transactions — 2023-03 3 derivative
    2023-02-21 00:00 UTCINSIDER23 insider transactions — 2023-02 · net buy $8.6M 6 derivative
    2023-02-21 00:00 UTCINSIDER23 insider transactions — 2023-02 · net buy $8.6M 6 derivative
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage